Rheumatoid arthritis (RA) is associated with a higher prevalence of infections, malignancies, osteoporotic fractures and cardiovascular diseases. Few data are available regarding the prevalence and severity of these comorbidities in elderly RA patients. The purpose of this study is to determine the effect of age on prevalence and severity of comorbidities in RA.
Prevalence of rheumatoid arthritis (RA) in elderly is increasing because of the increasing life expectancy. RA is associated with a higher prevalence of infections, malignancies, osteoporotic fractures and cardiovascular diseases. The purpose of this study is to determine the effect of age on prevalence and severity of comorbidities in RA. This study also aims to determine whether age influences disease progression and efficacy and tolerance of treatments. This study will compare two groups of patients : patients older than 65 years old and patients younger than 50 years old, matched for gender and disease duration. The first part of the study will be cross-sectional and will aim to compare characteristics regarding RA manifestations and comorbidities of the two groups at inclusion. Whereas the second part will be prospective to assess the occurrence of comorbidities and the efficacy and safety of treatments in these two groups. Patients will be assessed every year during 5 years in accordance with usual follow-up of the patients. This study could help to better manage elderly RA patients and to modify clinical practice.
Study Type
OBSERVATIONAL
Enrollment
176
Cochin hospital
Paris, Paris, France
Number of severe infections
Occurrence of severe infection requiring hospitalization or varicella-zoster virus
Time frame: 5 years
Number of cancers
Occurrence of solid cancer or hemopathy
Time frame: 5 years
Number of cardiovascular diseases
Occurrence of myocardial infarction or stroke
Time frame: 5 years
Number of osteoporotic fractures
Time frame: 5 years
Disease Activity Score (DAS 28)
to evaluate articular activity
Time frame: 5 years
Simple Disease Activity Index (SDAI)
to evaluate clinical articular activity of rheumatoid arthritis
Time frame: 5 years
Erythrocyte sedimentation rate
to evaluate biological articular activity of rheumatoid arthritis
Time frame: 5 years
Measure of C-reactive protein (CRP)
to evaluate biological articular activity of rheumatoid arthritis
Time frame: 5 years
Number of synovitis and/or tenosynovitis at ultrasound of hands
to evaluate articular activity of rheumatoid arthritis at ultrasound
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: 5 years
Health assessment questionnaire (HAQ) score
Time frame: 5 years
Need of orthopaedic surgery
to evaluate severity of rheumatoid arthritis
Time frame: 5 years
Number of erosions at X-rays (hands and feet)
to evaluate severity of rheumatoid arthritis
Time frame: 5 years
Number of diabetes, arterial hypertension and dyslipidaemia
to evaluate risks factor of cardiovascular disease
Time frame: 5 years
Number of cataracts
Time frame: 5 years
Number of vaccinations
Previous influenza vaccination within the previous year and pneumococcal vaccination within the previous 5 years will be searched during medical interview.
Time frame: 5 years